Tovanor Breezhaler यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

tovanor breezhaler

novartis europharm limited - bromid glycopyrronium - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - tovanor breezhaler je indiciran kao liječenje bronhodilatatora za održavanje kako bi se ublažili simptomi kod odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (copd).

Takhzyro यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

takhzyro

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedemas, nasljedni - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Emgality यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

emgality

eli lilly nederland b.v. - galcanezumab - migrena poremećaja - analgesics, galcanezumab - emgality je indiciran za prevenciju migrene kod odraslih koji imaju barem 4 dana migrene u mjesec.

Bevespi Aerosphere यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

bevespi aerosphere

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - plućna bolest, kronična opstruktivna - formoterol i bromid glycopyrronium - bevespi atmosferu prikazan kao terapiju održavanja бронходилататор za ublažavanje simptoma kod odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (kopb).

Sunosi यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

sunosi

atnahs pharma netherlands b.v. - solriamfetol hidroklorid - narcolepsy; sleep apnea, obstructive - psychoanaleptics, - sunosi pokazala da poboljšanje budnosti i smanjiti prekomjerna dnevna pospanost u odraslih bolesnika s narkolepsije (sa ili bez cataplexy). sunosi pokazala da poboljšanje budnosti i smanjiti prekomjerna dnevna pospanost (eds) kod odraslih pacijenata sa sindromom opstruktivna sleep apnea (osa), kod kojih je ЭЦП je nedovoljno obrađenih osnovnih osa terapija, kao što su kontinuirani pozitivni tlak u dišnim putevima (cpap stroj).

Bemrist Breezhaler यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Orladeyo यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - angioedemas, nasljedni - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Quviviq यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

quviviq

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - poremećaji uvođenja i održavanja spavanja - psycholeptics - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Tezspire यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

tezspire

astrazeneca ab - tezepelumab - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Pluvicto यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - tumori prostate, Кастраци-uporan - terapeutski radiofarmaceutski pripravci - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.